Intriguingly, a recent work on GC revealed that acetylcholine agonists promote cancer growth in vivo through the activation of epidermal growth factor (EGF) receptor signaling, which activates the MAPK and PI3K-Akt pathways [123]. This evidence concerns the gene AKT1 and cancer.